Cost-effectiveness of deep brain stimulation in patients with Parkinson's disease

Movement Disorders

Volumn 28, Issue 6, 2013, Pages 763-771

  Dams, Judith ^a   Siebert, Uwe ^b,c,d   Bornschein, Bernhard ^b   Volkmann, Jens ^e   Deuschl, Günther ^f   Oertel, Wolfgang H ^a   Dodel, Richard ^a   Reese, Jens Peter ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b UNIVERSITY FOR HEALTH SCIENCES   (Austria)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^e UNIVERSITY OF WÜRZBURG   (Germany)

^f UNIVERSITY OF KIEL   (Germany)

Author keywords

Cost effectiveness analysis; Deep brain stimulation; Dyskinesias; Markov model; Parkinson's disease

Indexed keywords

ADULT; ARTICLE; BRAIN DEPTH STIMULATION; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; FEMALE; HEALTH CARE PERSONNEL; HEALTH STATUS; HIDDEN MARKOV MODEL; HUMAN; MAJOR CLINICAL STUDY; MALE; PARKINSON DISEASE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS; UNIFIED PARKINSON DISEASE RATING SCALE;

COST-BENEFIT ANALYSIS; DEEP BRAIN STIMULATION; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PARKINSON DISEASE; QUALITY OF LIFE; SENSITIVITY AND SPECIFICITY;

EID: 84879603031     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.25407     Document Type: Article

References (46)

1. Twelves D, Perkins KS, Counsell C. Systematic review of incidence studies of Parkinson's disease. Mov Disord 2003;18:19-31.
2. von Campenhausen S, Bornschein B, Wick R, et al. Prevalence and incidence of Parkinson's disease in Europe. Eur Neuropsychopharmacol 2005;15:473-490.
3. Deuschl G, Schade Brittinger C, Krack P, et al. A randomized trial of deep-brain stimulation for Parkinson's disease. N Engl J Med 2006;355:896-908.
4. Weaver FM, Follett K, Stern M, et al. Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: a randomized controlled trial. JAMA 2009;301:63-73.
5. Kleiner-Fisman G, Fisman DN, Sime E, Saint-Cyr JA, Lozano AM, Lang AE. Long-term follow up of bilateral deep brain stimulation of the subthalamic nucleus in patients with advanced Parkinson disease. J Neurosurg 2003;99:489-495.
6. Valldeoriola F, Morsi O, Tolosa E, Rumia J, Marti MJ, Martinez-Martin P. Prospective comparative study on cost-effectiveness of subthalamic stimulation and best medical treatment in advanced Parkinson's disease. Mov Disord 2007;22:2183-2191.
7. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967;17:427-442.
8. Fraix V, Houeto JL, Lagrange C, et al. Clinical and economic results of bilateral subthalamic nucleus stimulation in Parkinson's disease. J Neurol Neurosurg Psychiatry 2006;77:443-449.
9. Schöffski O, Graf von der Schulenburg JM. Gesundheitsökonomische Evaluationen. Berlin, Germany: Springer; 2007.
10. Martilla RJ, Rinne UK. Disability and progression in Parkinson's disease. Acta Neurol Scand 1977;56:159-169.
11. Bejjani BP, Gervais D, Arnulf I, et al. Axial parkinsonian symptoms can be improved: the role of levodopa and bilateral subthalamic stimulation. J Neurol Neurosurg Psychiatry 2000;68:595-600.
12. Däuper J, Peschel T, Schrader C, et al. Effects of subthalamic nucleus (STN) stimulation on motor cortex excitability. J Neurol 2002;59:700-706.
13. Hilker R, Voges J, Ghaemi M, et al. Deep brain stimulation of the subthalamic nucleus does not increase the striatal dopamine concentration in parkinsonian humans. Mov Disord 2003;18:41-48.
14. Jahanshahi M, Ardouin CM, Brown RG, et al. The impact of deep brain stimulation on executive function in Parkinson's disease. Brain 2000;123:1142-1154.
15. Pinter MM, Alesch F, Murg M, Helscher RJ, Binder H. Apomorphine test: a predictor for motor responsiveness to deep brain stimulation of the subthalamic nucleus. J Neurol 1999;246:907-913.
16. Krack P, Batir A, van Blercom N, et al. Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson's disease. N Engl J Med 2003;349):1925-1934.
17. Spottke EA, Volkmann J, Lorenz D, et al. Evaluation of healthcare utilization and health status of patients with Parkinson's disease treated with deep brain stimulation of the subthalamic nucleus. J Neurol 2002;249:759-766.
18. Federal Statistical Office. Statistisches Jahrbuch 2009. Wiesbaden, Germany; SFG Servicecenter Fachverlage. 2009.
19. Wermuth L, Stenager EN, Stenager E, et al. Mortality in patients with Parkinson's disease Acta Neurol Scand 1995;92:55-58.
20. Volkmann J. Update on surgery for Parkinson's disease. Curr Opin Neurol 2007;20:465-469.
21. Federal Statistical Office. Statistisches Jahrbuch 2010. Consumer price Index. Wiesbaden, Germany: SFG Servicecenter Fachverlage. 2010.
22. Spottke AE, Reuter M, Machat O, et al. Cost of illness and its predictors for Parkinson's disease in Germany. Pharmacoeconomics 2005;23:817-836.
23. Liang GS, Chou KL, Baltuch GH, et al. Long-term outcomes of bilateral subthalamic nucleus stimulation in patients with advanced Parkinson's disease. Stereotact Funct Neurosurg 2006;84(5-6):221-227.
24. Østergaard K, Aa Sunde N. Evolution of Parkinson's disease during 4 years of bilateral deep brain stimulation of the subthalamic nucleus. Mov Disord 2006;21:624-631.
25. Rodriguez-Oroz MC, Gorospe A, Guridi J, et al. Bilateral deep brain stimulation of the subthalamic nucleus in Parkinson's disease. J Neurol 2000;55(suppl 6):S45-S51.
26. Kleiner-Fisman G, Herzog J, Fisman DN, et al. Subthalamic nucleus deep brain stimulation: summary and meta-analysis of outcomes. Mov Disord 2006;21(suppl 14):S290-S304.
27. Clarke CE, Worth P, Grosset D, Stewart D. Systematic review of apomorphine infusion, levodopa infusion and deep brain stimulation in advanced Parkinson's disease. Parkinsonism Relat Disord 2009;15:728-741.
28. Institute for Quality and Efficiency in Health Care [Internet]. Cologne (Germany): Methods for Assessment of the Relation of Benefits to Costs in the German Statutory Health Care System. 2008. [cited 2012 Jan 8]. Available from: http://www.iqwig.de/
29. Medical Advisory Secretariat, Ontario Ministry of Health and Long-Term Care. Deep Brain Stimulation for Parkinson's Disease and other Movement Disorders: An Evidence-Based Analysis [structured abstract]. Toronto, Ontario, Canada: Medical Advisory Secretariat, Ontario Ministry of Health and Long-Term Care; 2005.
30. Anheim M, Fraix V, Chabardes S, Krack P, Benabid AL, Pollak P. Lifetime of Itrel II pulse generators for subthalamic nucleus stimulation in Parkinson's disease. Mov Disord 2007;22:2436-2439.
31. Ondo WG, Meilak C, Vuong KD. Predictors of battery life for the Activa Soletra 7426 neurostimulator. Parkinsonism Relat Disord 2007;13:240-242.
32. Laupacis A, Feeny D, Detsky AS, Tugwell PX. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. Can Med Assoc J 1992;146:473-481.
33. Siebert U, Bornschein B, Walbert T, et al. Systematic assessment of decision models in Parkinson's disease. Value Health 2004;7:610-626.
34. World Health Organization. Making choices in health: WHO guide to cost-effectiveness analysis. Geneva: World Health Organization; 2003.
35. National Collaborating Centre for Chronic Conditions (UK). Parkinson's disease: National clinical guideline for diagnosis and management in primary and secondary care. Appendix F. London, United Kingdom: Royal College of Physicians; 2006.
36. Tomaszewski KJ, Holloway RG. Deep brain stimulation in the treatment of Parkinson's disease: a cost-effectiveness analysis. J Neurol 2001;57:663-671.
37. Torrance GW, Feeny D, Furlong W. Visual analog scales: do they have a role in the measurement of preferences for health states? Med Decis Making 2001;21:329-334.
38. Meissner W, Schreiter D, Volkmann J, et al. Deep brain stimulation in late stage Parkinson's disease: a retrospective cost analysis in Germany. J Neurol 2005;252:218-223.
39. von Campenhausen S, Winter Y, Rodrigues e Silva A, et al. Costs of illness and care in Parkinson's disease: an evaluation in six countries. Eur Neuropsychopharmacol 2011;21:180-191.
40. Schrag A, Selai C, Jahanshahi M, Quinn NP. The EQ-5D-a generic quality of life measure-is a useful instrument to measure quality of life in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 2000;69:67-73.
41. Espay AJ, Vaughan JE, Marras C, Fowler R, Eckman MH. Early versus delayed bilateral subthalamic deep brain stimulation for Parkinson's disease: a decision analysis. Mov Disord 2010;25:1456-1463.
42. Dams J, Bornschein B, Reese JP, Conrads-Frank A, Siebert U, Dodel R. Modelling the cost effectiveness of treatments for Parkinson's disease: a methodological review. Pharmacoeconomics 2011;29:1025-1049.
43. Halpern CH, McGill KR, Baltuch GH, Jaggi JL. Longevity analysis of currently available deep brain stimulation devices. Stereotact Funct Neurosurg 2011;89:1-5.
44. Valldeoriola F, Pilleri M, Tolosa E, Molinuevo JL, Rumia J, Ferrer E. Bilateral subthalamic stimulation monotherapy in advanced Parkinson's disease: long-term follow-up of patients. Mov Disord 2002;17:125-132.
45. Schüpbach WM, Chastan N, Welter ML, et al. Stimulation of the subthalamic nucleus in Parkinson's disease: a 5 year follow up. J Neurol Neurosurg Psychiatry 2005;76:1640-1644.
46. Group EuroQuol. EuroQuol: a new facility for the measurement of health-related 505 quality of life. Health Policy 1990;16:199-208.